Laboratory of Connective tissue disease
Main Research FieldClinical and Translational Research for Autoimmune Diseases and Connective Tissue Pathology
Research Subjects
- Paracrine regulation of connective tissue remodeling
- Inflammation and angiogenesis in rheumatic diseases
- New biomarkers of connective tissue diseases
- Development of prognostic criteria of biologic therapy clinical efficiency
- Genetics of rheumatic diseases
- Assessment of new anti rheumatic drugs
- Osteoporosis in rheumatic diseases
Head of Laboratory
Maksim A. Korolev, MD, PhD
Dr. M. Korolev graduated from the Medical Faculty of the Novosibirsk Medical Institute in 1995. He took postgraduate training courses in Rheumatology in Sechenov Medical Academy (Moscow), St. Johanns Spital in Salzburg, (Austria), University Clinic in Budapest (Hungary). In 2008 he defended his PhD thesis on the clinical and immunological characteristics of the sexually-acquired reactive arthritis . In 2007 Dr. M. Korolev had received the second higher education in the specialty «Economics and Management in the Healthcare», (Novosibirsk State Medical University).
His current scientific and research Interests are in pathogenesis, genetics and targeting treatment of the rheumatic diseases, development of prognostic criteria of biologic therapy clinical efficiency, assessment of new antirheumatic drugs, osteoporosis in rheumatic diseases. M. Korolev current position is a Deputy Director for Science and Clinic in the Scientific Institute of Clinical and Experimental Lymphology. Dr. M. Korolev is a member of Association of Rheumatologists of Russia (ARR), Russian Association on Osteoporosis (RAO) and European League Against Rheumatism (EULAR). His is author of more than 40 articles in peer-review journals, co-author of 4 monographs and 3 patents. His research projects were supported by the grants from the Ministry of Education and Science of the Russian Federation.
Selected Publications
1. Analysis of the state-of-the-art of consulting medical care to patients with glucocorticoid-induced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study). Baranova IA, Ershova OB, Anaev EKh, Anokhina TN, Anoshenkova ON, Batyn SZ, Belyaeva EA, Bolshakova TY, Volkorezov IA, Eliseeva LN, Kashnazarova EV, Kinyaikin MF, Kirpikova MN, Klyuchnikova EP, Korolev MA, Kuneevskaya IV, Masneva LV, Muradyants AA, Otteva EN, Petrachkova TN, Peshekhonova LK, Povzun AS, Raskina TA, Smirnova ML, Toroptsova NV, Khasanova RB, Shamsutdinova NG, Shaporova NL, Shitova NS, Shkireeva SY, Shostak NA, Lesnyak OM. Ter Arkh. 2015;87(5):58-64.
2. Matrix metalloproteinase 2, 3, and 9 gene polymorphisms in women with rheumatoid arthritis. Shevchenko AV, Konenkov VI, Korolev MA, Ubshaeva YB, Prokofiev VF. Ter Arkh. 2015;87(12):36-40.
3. Genetic factors of angiogenic dysregulation in women with rheumatoid arthriti]. Konenkov VI, Korolev MA, Shevchenko AV, Prokofyev VF, Ubshaeva YB, Sokolova OS, Letyagina EA, Dyubanova GA. Ter Arkh. 2013;85(5):16-23.
4. Vascular endothelial growth factor gene polymorphism in patients with rheumatoid arthritis. Korolev M., Konenkov V., Prokofyev V., Shevchenko A., Zonova E. Annals of the Rheumatic Diseases. 2012. Т. 71. № 3. С. 638.
5. Cytokine gene polymorphism in type 2 diabetes mellitus in Russian women from eastern Europe. Konekov VI, Korolev MA, Shevchenko AV, Lapsina CA, Koroleva EA, Zonova EV, Prokof'ev VF. Ter Arkh. 2012;84(10):14-22.
6. Distribution of allelic variants of promotor sites of cytokine genes and endothelial growth factor gene among healthy subjects and patients with rheumatoid arthritis in a Russian Europeoid populatio. Konenkov VI, Golovanova OV, Prokof'ev VF, Shevchenko AV, Zonova EV, Korolev MA, Leonova IuB, Khalaĭdzhi NA, Lapsina SA. Vestn Ross Akad Med Nauk. 2010;(9):9-14.
7. Pharmacogenenetics in disease-modifying antirheumatic drugs treatment of rheumatoid arthritis. Konenkov V., Zonova E., Shevchenko A., Golovanova O., Prokofyev V., Khalajdzhi N., Korolev M.Annals of the Rheumatic Diseases. 2010. Т. 69. № 3. С. 661.
8. Comparative analysis of allelic variants of promotor sites of cytokine genes il1b c-31t,il6 g-174c,tnfa a-238g,tnfa a-308g,tnfa a-863c,il4 c-590t,il10 a-592c,vegf c-2578a among healthy caucasoids and rheumatoid arthritis patients in russia. Konenkov V.I., Prokofiev V.F., Golovanova O.V., Shevchenko A.V., Zonova E.V., Korolev M.A., Leonova J., Khalajdzhi N.A. Annals of the Rheumatic Diseases. 2010. Т. 69. № 3. С. 665.
9. Pharmacogenetic criteria for the efficacy of basic anti-inflammatory therapy for rheumatoid arthriti]. Konenkov VI, Zonova EV, Korolev MA, Leonova IuB, Shevchenko AV, Golovanova OV, Prokof'ev VF. Ter Arkh. 2010;82(12):56-61.
10. Can immunogenetic factors be used to predict development sexually acquired reactive arthritis in patients with urogenital infection? Korolev M.A., Zonova E.V., Golovanova O.V., Shevchenko A.V., Letyagina E.A., Konenkov V.I. Annals of the Rheumatic Diseases. 2009. Т. 68. № 3. С. 683.
11. Zoledronic acid and clinical fractures and mortality after hip fracture. Kenneth W., Lyles M.D., Cathleen S., Colon-Emeric M.D., Korolev M.A., Koroleva E.A. New England Journal of Medicine. 2007. Т. 357. № 18. С. 1800-1809.
12. Successful treatment of refractory chronic gouty arthritis with infliximab. Korolev M.A., Zonova E.V., Konenkov V.I. Annals of the Rheumatic Diseases. 2006. Т. 65. № 2. С. 434.
13. Association of TAP1/TAP2 gene polymorphism with inflammatory urogenital diseases combined with joint disease]. Sartakova ML, Konenkov VI, Shevchenko AV, Golovanova OV, Konenkova LP, Zonova EV, Korolev MA. Ter Arkh. 1999;71(11):41-5.
14. M.A. Korolev, Y.B. Ubshaeva, E.A. Letyagina, A.V. Shevchenko, V.F. Prokof’yev, V.I. Konenkov Association of polymorphisms in the matrix metalloproteinase genes with extra-articular symptoms of rheumatoid arthritis / SBioMed-2016, Abstracts, Novosibirsk, Russia 30–31 August, 2016., P.47
15. V.O. Omelchenko, M.A. Korolev , E.A. Letyagina , A.V. Shevchenko , V.F. Prokof’yev , T.I. Pospelova , V.I. Konenkov Polymorphisms in the genes of vascular endothelial growth factor are associated with the earlier onset of rheumatoid arthritis / SBioMed-2016, Abstracts, Novosibirsk, Russia 30–31 August, 2016., P. 69.
16. L.N. Rachkovskaya, T.V. Popova , A. Yu Letyagin, T.G. Tolstikova, M.A. Korolev, N. Bogdanchikova, A.N. Pestryakov, A.A. Kotlyarova, V. Burmistrov, V.I. Konenkov Silver containing sorbents: Physicochemical and biological properties / Resource-Efficient Technologies, 2 (2016), P. 43–49
17. Королев М.А., Прудникова М.А., Летягина Е.А., Акимова А.А., Омельченко В.О., Коненков В.И. Распространенность остеопороза при различных формах спондилоартритов // Российский конгресс по остеопорозу, остеоартрозу и другим метаболическим заболеваниям скелета. Казань, 8-10 сент. 2016 г. Секция: «Остеопороз в ревматологии».
18. Korolev M.A. Molecular basis for targeted therapy of autoimmune diseases // SBioMed-2016, Новосибирск, Секция: Personalized Medicine: New Biomarkers and Molecular Targets
19. Korolev M. A.*, Ubshaeva Y. B., Letyagina E. A., Shevchenko A. V., Prokof’yev V. F., Konenkov V.I. ASSOCIATION OF MATRIX METALLOPROTEINASES GENE POLYMORPHISM WITH THE RISK OF DEVELOPING EXTRA-ARTICULAR SYMPTOMS OF RHEUMATOID ARTHRITIS // SBioMed-2016, Novosibirsk, Russia, 2016, Abstracts, P. 47.
20. Omelchenko V.O.1*, Korolev M. A.1, Letyagina E. A.1, Shevchenko A. V.1, Prokof’yev V. F.1, Pospelova T. I.2, Konenkov V. I. VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS ARE ASSOCIATED WITH THE EARLIER ONSET OF RHEUMATOID ARTHRITIS // SBioMed-2016, Novosibirsk, Russia, 2016, Abstracts, P. 69.
21. Prokof'ev V.F., Shevchenko A.V., Korolev M.A., Konenkov V.I. USING THE TECHNIQUES OF STOCHASTIC MODELLING AND INHOMOGENEOUS SEQUENTIAL PATTERN RECOGNI-TION PROCEDURE FOR THE PREDICTION OF POLYGENIC DISEASES // В книге: THE INTERNATIONAL SYMPOSIUM SYSTEMS BIOLOGY AND BIOMEDICINE (SBioMed-2016) Abstracts. 2016. С. 85.
Clinical Trials
A4091058 «A phase 3 randomized, double-blind, active-controlled, multicenter study of the long-term safety and efficacy of subcutaneous administration of tanezumab in subjects with osteoarthritis of the hip or knee»
CL2-78989-012 «A randomised, double-blind, placebo-controlled proof of concept study of the efficacy and the safety of gevokizumab in the treatment of patients with giant cell arteritis»
CNTO136ARA3005 «A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (sirukumab) Administered Subcutaneously as Monotherapy Compared With Adalimumab Monotherapy, in Subjects with Active Rheumatoid Arthritis»
CLCZ696B2317 «A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696»
Contacts
Arbuzova Street 6, 630117, Novosibirsk, Russia
Tel. +7-383-332-29-50
E-mail: kormax@bk.ru
